Personalised to support your treatment decisions
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the . Phase III trial of Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).
Genmab announced very favorable topline results from the Phase II single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer.
Helsinn and MEI Pharma have discontinued a Phase III trial of SB 393 (pracinostat) in combination with Vidaza (azacitidine) in patients with acute myeloid leukaemia (AML) who are unsuitable for standard intensive chemotherapy.
You may be interested in...
6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation.
The Haematological Tumour Microenvironment and its Therapeutic Targeting 2021
This workshop brings together a constantly growing and international community of researchers, physicians and physician scientists, as well as biologists and physicians in training and corporate representatives, whose present or future work is focused on the tumor microenvironment in the haematological malignancies.